The underlying field was recognized this week when the 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, MD ...
At month 3, the 149-eye trial found a 7.4 mmHg reduction with surgery alone; iDose had no serious corneal adverse events ...
Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about ...
19hon MSN
Involuntary eye movements could be targeted by restoring retinal dopamine, mouse experiments suggest
Researchers have found a possible way to stop abnormal signals in the retina that are linked to involuntary eye movements (nystagmus). In experiments on mouse retinas in the lab, restoring dopamine ...
Investigators presented 12-month phase 2 data on subretinal OCU410 gene therapy in patients with geographic atrophy.
Visual impairment poses a growing public health challenge in the United States, with 3.22 million people affected in some way, including 1.02 million individuals experiencing blindness as of 2015.
Perceive Biotherapeutics, Inc. ("Perceive Bio" or the "Company"), a biotechnology company advancing novel gene therapies in ophthalmology and adjacent indications, today announced the completion of ...
Glaukos Corporation (NYSE:GKOS) reported three-year trial results for its non-invasive keratoconus treatment while ...
Korea University Ophthalmology data show macular degeneration cases doubled in 10 years as high myopia and metabolic diseases ...
Glaukos reported three-year Phase 3 extension results for Epioxa, showing sustained corneal improvement and visual gains ...
A first-of-its-kind motion capture study shows that blind and severely visually impaired skiers lean significantly more ...
- Glaukos GKOS -6.32% (GKOS) stock fell 6.32% on Oct 8, 2026, despite $0.45B in trading volume, its highest daily turnover. - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results